Journal
MEDICINAL RESEARCH REVIEWS
Volume 28, Issue 6, Pages 929-953Publisher
WILEY
DOI: 10.1002/med.20128
Keywords
antivirals; valaciclovir; BVDU; DHPA; cidofovir; adefovir; tenofovir; stavudine; HEPT; TIBO; AMD3100
Categories
Ask authors/readers for more resources
This review article, while autobiographical to some extent, describes the discovery often (classes of) antiviral compounds that have made (or just did not make) it to the market for the therapy of viral infections, but each in its own way influenced the landscape of our dealing with virus infections: (i) valaciclovir, (ii) BVDU, (iii) DHPA, (iv) cidofovir, (v) adefovir, (vi) tenofovir, (vii) stavudine, (viii) HEPT, (ix) TIBO, and (x) AMD3100. Successful drug development, as is certainly true for antiviral drugs and exemplified for the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir, requires patience and perseverance, and a close continuous and dedicated interaction between Chemistry, Biology/Medicine and Industry. (C) 2008 Wiley Periodicals, Inc. Med Res Rev, 28, No. 6, 929-953, 2008
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available